Improved productivity contributes to assessments of pharmaceutical value
The Institute for Clinical and Economic Review (ICER) is a non-profit organization that weighs the costs of prescription drugs against their clinical and social value. Their method is complex, but essentially it designates drugs as "high value" if they deliver an additional, quality-adjusted life year (QALY) for less than $50,000, and "low value" if the [...]